Portfolio company Inivata, which employing the precision of ctDNA analysis to improve personalised healthcare in oncology, has completed a £31.5 million Series A fundraising.
The round saw the participation of existing investors Imperial Innovations, Cambridge Innovation Capital, and Johnson and Johnson Innovation alongisde new investor Woodford Patient Capital Trust. Innovations has committed £10.0 million to the round.
Inivata is harnessing the emerging potential of circulating DNA analysis to improve testing and treatment in oncology. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample.
Dr Rob Woodman, Director of Healthcare Ventures, Imperial Innovations added:
“Analysis of ctDNA has the potential to transform cancer care and resolve many of the limitations inherent in current tissue-based standard protocols that are highly invasive and are not amenable to serial monitoring.
“Innovations’ led a seed financing round for Inivata in September 2014. The fact that the company has secured funding of this size reflects the great progress the Company has made in such a short time, not least in developing innovative molecular profiling and monitoring products."